Pre-market volume spike: 0383.HK Tian An Medicare HKSE +10.53% watch HKD 1.20 25 Mar 2026

A sharp pre-market volume surge pushed 0383.HK stock up to HKD 1.05, a 10.53% gain from the previous close on heavy turnover. The spike shows 2,459,000 shares traded versus an average of 5,305, giving a relative volume of 463.52x. This sudden interest comes as the healthcare sector in Hong Kong trades weaker year-to-date, so the move may reflect short-term flows or a news-driven reposition. We unpack technical triggers, valuation signals and price targets for Tian An Medicare Limited (0383.HK) on the HKSE.

Volume spike and price action on 0383.HK stock

Trading volume jumped to 2,459,000 shares compared with an average volume of 5,305, signalling a clear volume spike. The stock opened at HKD 1.10, hit an intraday high of HKD 1.36, and closed pre-market print at HKD 1.05, above the prior close of HKD 0.95.

High relative volume alongside a move above the 50-day average (HKD 0.96) suggests short-term momentum traders are active. Watch immediate resistance at HKD 1.20 and year-high HKD 1.36 as technical barriers that could limit gains.

Technical signals and trading setup for 0383.HK stock

Momentum indicators are stretched: RSI at 71.26 and MFI at 98.51 indicate overbought conditions, while ADX at 70.10 shows a strong trend. MACD histogram is modestly positive, supporting continuation but cautioning on a near-term pullback.

Given the volume spike, an intraday breakout above HKD 1.20 on follow-through volume could open a quick target to HKD 1.36. Failure to hold HKD 1.00 would increase downside risk toward the 200-day average of HKD 0.95.

Fundamentals and valuation: 0383.HK stock analysis

Tian An Medicare reports EPS of -0.02 and a trailing PE of -52.50, reflecting near-term negative earnings. Key valuation ratios show Price-to-Sales 0.68 and Price-to-Book 0.64, implying the market values the company below book on a P/B basis.

Balance-sheet metrics include current ratio 2.15 and debt-to-equity 0.50, suggesting reasonable liquidity and leverage. Free cash flow per share is negative at -0.03, so operational cash conversion needs monitoring as the company scales eldercare and medical services.

Meyka AI rates 0383.HK with a score out of 100 and forecast

Meyka AI rates 0383.HK with a score out of 100: 61.42 (Grade B, Suggestion: HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus.

Meyka AI’s forecast model projects a yearly price of HKD 1.12, a 3-year target of HKD 1.53 and a 5-year target of HKD 1.94. Compared with the current price HKD 1.05, the one-year projection implies an upside of 6.62%. Forecasts are model-based projections and not guarantees.

Catalysts, sector context and risks for 0383.HK stock

Catalysts that could sustain the volume spike include additional eldercare contract wins, hospital admissions growth, or asset disposals tied to property segments. Healthcare sector performance has fallen 7.08% YTD, so outperformance by Tian An Medicare could draw rotation flows.

Risks include negative EPS trends, cash conversion weakness, and sensitivity to China healthcare policy. Company-level exposure to property development and securities trading adds cyclicality versus pure-play healthcare peers.

Practical trading plan and price targets for 0383.HK stock

For active traders, consider a breakout plan: enter on a confirmed close above HKD 1.20 with stop at HKD 1.00 and initial target HKD 1.36. For position traders, a conservative base case target is the Meyka one-year forecast HKD 1.12, with a three-year target HKD 1.53 for a bull scenario.

Risk management should limit position size given EPS is negative and the stock shows volatile intraday swings. Monitor volume and sector flows closely before adding exposure.

Final Thoughts

The pre-market volume spike in 0383.HK stock is a clear short-term market signal: 2,459,000 shares traded, far above the average of 5,305, and price moved to HKD 1.05. Technicals show overbought momentum, so traders should wait for confirmation above HKD 1.20 or protect downside at HKD 1.00. On fundamentals, Tian An Medicare (0383.HK) displays attractive P/B 0.64 and P/S 0.68, but negative EPS -0.02 and negative free cash flow per share -0.03 introduce medium-term risk. Meyka AI’s forecast model projects HKD 1.12 in 12 months, implying an upside of 6.62% from HKD 1.05. These forecasts are model outputs and not guarantees. Given the healthcare sector headwinds YTD and the firm’s mixed cash-flow metrics, we present a balanced view: short-term traders can trade the momentum set-up, while longer-term investors should weigh the Meyka grade (61.42, B, HOLD) and watch operational cash flow and earnings improvements before adding larger positions. For live quotes and filings visit the company site and our Meyka stock page for real-time updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.